The findings shared at #AADInnovation2026 reinforce the promise of this approach and the importance of continuing to advance treatment options
Other Peptides of Interest Cerebrolysin: The Most-Studied Cognitive PeptideYet Not FDA-Approved Cerebrolysin presents a regulatory paradox: it has more clinical trial data than any other cognitive peptide, is approved in over 50 countries, has been used clinically for decadesyet remains unavailable in the United States
This guide examines the current scientific evidence supporting GHK-Cu's mechanisms of action, including its effects on collagen synthesis, inflammation, and cellular gene expression - providing context for those investigating this peptide in research and educational settings
Retatrutide is currently advancing through the TRIUMPH Phase 3 clinical program , which spans obesity, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and cardiovascular outcomes
26 March 2024